An international collaboration led by Flinders University identified a potential biomarker for ALS/MND, providing a way to test the effectiveness of future clinical trials.
The team identified that the concentration of neopterin – a small molecule released by immune cells in response to inflammation and secreted in urine – increased as ALS/MND progressed. Read more here.
